Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9548 |
High Similarity |
NPD3921 |
Approved |
0.9548 |
High Similarity |
NPD3923 |
Approved |
0.9548 |
High Similarity |
NPD3922 |
Approved |
0.9548 |
High Similarity |
NPD3924 |
Approved |
0.9362 |
High Similarity |
NPD3816 |
Phase 1 |
0.9362 |
High Similarity |
NPD3815 |
Phase 1 |
0.8927 |
High Similarity |
NPD3920 |
Phase 2 |
0.85 |
High Similarity |
NPD3763 |
Approved |
0.8486 |
Intermediate Similarity |
NPD6257 |
Clinical (unspecified phase) |
0.8315 |
Intermediate Similarity |
NPD7414 |
Clinical (unspecified phase) |
0.8307 |
Intermediate Similarity |
NPD6569 |
Phase 2 |
0.819 |
Intermediate Similarity |
NPD6494 |
Phase 2 |
0.8186 |
Intermediate Similarity |
NPD5070 |
Clinical (unspecified phase) |
0.8182 |
Intermediate Similarity |
NPD5658 |
Approved |
0.8182 |
Intermediate Similarity |
NPD4889 |
Approved |
0.8142 |
Intermediate Similarity |
NPD1923 |
Clinical (unspecified phase) |
0.8102 |
Intermediate Similarity |
NPD6230 |
Discontinued |
0.8031 |
Intermediate Similarity |
NPD4418 |
Discontinued |
0.803 |
Intermediate Similarity |
NPD4122 |
Approved |
0.803 |
Intermediate Similarity |
NPD4039 |
Approved |
0.803 |
Intermediate Similarity |
NPD4034 |
Approved |
0.803 |
Intermediate Similarity |
NPD4037 |
Approved |
0.803 |
Intermediate Similarity |
NPD4036 |
Approved |
0.803 |
Intermediate Similarity |
NPD4033 |
Approved |
0.803 |
Intermediate Similarity |
NPD32 |
Approved |
0.803 |
Intermediate Similarity |
NPD31 |
Approved |
0.803 |
Intermediate Similarity |
NPD4038 |
Approved |
0.803 |
Intermediate Similarity |
NPD4035 |
Approved |
0.801 |
Intermediate Similarity |
NPD6219 |
Discontinued |
0.8 |
Intermediate Similarity |
NPD5863 |
Clinical (unspecified phase) |
0.799 |
Intermediate Similarity |
NPD3477 |
Phase 2 |
0.799 |
Intermediate Similarity |
NPD3478 |
Clinical (unspecified phase) |
0.7953 |
Intermediate Similarity |
NPD7729 |
Clinical (unspecified phase) |
0.795 |
Intermediate Similarity |
NPD7222 |
Phase 2 |
0.7931 |
Intermediate Similarity |
NPD7069 |
Discontinued |
0.7923 |
Intermediate Similarity |
NPD6872 |
Clinical (unspecified phase) |
0.785 |
Intermediate Similarity |
NPD4795 |
Phase 2 |
0.7846 |
Intermediate Similarity |
NPD6861 |
Clinical (unspecified phase) |
0.7839 |
Intermediate Similarity |
NPD6477 |
Clinical (unspecified phase) |
0.7814 |
Intermediate Similarity |
NPD2782 |
Approved |
0.7814 |
Intermediate Similarity |
NPD2780 |
Approved |
0.7814 |
Intermediate Similarity |
NPD6963 |
Approved |
0.7814 |
Intermediate Similarity |
NPD6964 |
Approved |
0.7795 |
Intermediate Similarity |
NPD1304 |
Clinical (unspecified phase) |
0.7795 |
Intermediate Similarity |
NPD4551 |
Phase 2 |
0.7795 |
Intermediate Similarity |
NPD1038 |
Approved |
0.7768 |
Intermediate Similarity |
NPD4926 |
Clinical (unspecified phase) |
0.7767 |
Intermediate Similarity |
NPD6140 |
Clinical (unspecified phase) |
0.7761 |
Intermediate Similarity |
NPD3397 |
Phase 2 |
0.7754 |
Intermediate Similarity |
NPD5602 |
Clinical (unspecified phase) |
0.7743 |
Intermediate Similarity |
NPD8091 |
Phase 3 |
0.7737 |
Intermediate Similarity |
NPD3386 |
Phase 2 |
0.773 |
Intermediate Similarity |
NPD2781 |
Approved |
0.7729 |
Intermediate Similarity |
NPD5612 |
Discontinued |
0.7723 |
Intermediate Similarity |
NPD5530 |
Phase 1 |
0.7721 |
Intermediate Similarity |
NPD4885 |
Approved |
0.7685 |
Intermediate Similarity |
NPD7452 |
Approved |
0.7685 |
Intermediate Similarity |
NPD7453 |
Approved |
0.7653 |
Intermediate Similarity |
NPD7675 |
Phase 3 |
0.7653 |
Intermediate Similarity |
NPD7674 |
Phase 3 |
0.7653 |
Intermediate Similarity |
NPD7676 |
Clinical (unspecified phase) |
0.765 |
Intermediate Similarity |
NPD4396 |
Clinical (unspecified phase) |
0.765 |
Intermediate Similarity |
NPD1740 |
Approved |
0.765 |
Intermediate Similarity |
NPD1739 |
Approved |
0.7647 |
Intermediate Similarity |
NPD1078 |
Clinical (unspecified phase) |
0.7633 |
Intermediate Similarity |
NPD7571 |
Clinical (unspecified phase) |
0.7621 |
Intermediate Similarity |
NPD4131 |
Phase 3 |
0.76 |
Intermediate Similarity |
NPD4118 |
Clinical (unspecified phase) |
0.7577 |
Intermediate Similarity |
NPD4375 |
Approved |
0.7571 |
Intermediate Similarity |
NPD6568 |
Discontinued |
0.7566 |
Intermediate Similarity |
NPD7859 |
Phase 2 |
0.7552 |
Intermediate Similarity |
NPD4203 |
Approved |
0.7552 |
Intermediate Similarity |
NPD4204 |
Approved |
0.7549 |
Intermediate Similarity |
NPD5601 |
Phase 2 |
0.7546 |
Intermediate Similarity |
NPD8052 |
Clinical (unspecified phase) |
0.7536 |
Intermediate Similarity |
NPD6501 |
Approved |
0.7536 |
Intermediate Similarity |
NPD6500 |
Approved |
0.7536 |
Intermediate Similarity |
NPD4502 |
Phase 2 |
0.7535 |
Intermediate Similarity |
NPD6553 |
Clinical (unspecified phase) |
0.7526 |
Intermediate Similarity |
NPD6344 |
Clinical (unspecified phase) |
0.7523 |
Intermediate Similarity |
NPD7719 |
Discontinued |
0.7523 |
Intermediate Similarity |
NPD4876 |
Phase 3 |
0.7523 |
Intermediate Similarity |
NPD4875 |
Phase 3 |
0.7513 |
Intermediate Similarity |
NPD2334 |
Discontinued |
0.7512 |
Intermediate Similarity |
NPD3825 |
Phase 3 |
0.7512 |
Intermediate Similarity |
NPD1856 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD5930 |
Phase 3 |
0.7488 |
Intermediate Similarity |
NPD7426 |
Phase 1 |
0.7487 |
Intermediate Similarity |
NPD1032 |
Phase 2 |
0.7487 |
Intermediate Similarity |
NPD2917 |
Approved |
0.7476 |
Intermediate Similarity |
NPD5529 |
Phase 1 |
0.7476 |
Intermediate Similarity |
NPD2739 |
Clinical (unspecified phase) |
0.7476 |
Intermediate Similarity |
NPD5528 |
Clinical (unspecified phase) |
0.7474 |
Intermediate Similarity |
NPD5083 |
Clinical (unspecified phase) |
0.7465 |
Intermediate Similarity |
NPD5147 |
Discontinued |
0.7463 |
Intermediate Similarity |
NPD2060 |
Approved |
0.7449 |
Intermediate Similarity |
NPD1034 |
Phase 3 |
0.7449 |
Intermediate Similarity |
NPD1033 |
Clinical (unspecified phase) |
0.7443 |
Intermediate Similarity |
NPD7558 |
Phase 2 |
0.7441 |
Intermediate Similarity |
NPD7823 |
Clinical (unspecified phase) |
0.7436 |
Intermediate Similarity |
NPD7424 |
Clinical (unspecified phase) |
0.743 |
Intermediate Similarity |
NPD1954 |
Phase 1 |
0.7426 |
Intermediate Similarity |
NPD3541 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD5522 |
Clinical (unspecified phase) |
0.7418 |
Intermediate Similarity |
NPD6242 |
Discontinued |
0.7409 |
Intermediate Similarity |
NPD2600 |
Approved |
0.7409 |
Intermediate Similarity |
NPD2599 |
Approved |
0.7409 |
Intermediate Similarity |
NPD2601 |
Approved |
0.7406 |
Intermediate Similarity |
NPD3354 |
Phase 2 |
0.74 |
Intermediate Similarity |
NPD3396 |
Approved |
0.74 |
Intermediate Similarity |
NPD3395 |
Approved |
0.7396 |
Intermediate Similarity |
NPD5751 |
Clinical (unspecified phase) |
0.7396 |
Intermediate Similarity |
NPD4071 |
Approved |
0.7396 |
Intermediate Similarity |
NPD4072 |
Approved |
0.7387 |
Intermediate Similarity |
NPD4372 |
Phase 1 |
0.7374 |
Intermediate Similarity |
NPD6281 |
Approved |
0.7366 |
Intermediate Similarity |
NPD112 |
Approved |
0.7366 |
Intermediate Similarity |
NPD9705 |
Discontinued |
0.7352 |
Intermediate Similarity |
NPD4995 |
Approved |
0.7352 |
Intermediate Similarity |
NPD4996 |
Approved |
0.7351 |
Intermediate Similarity |
NPD2581 |
Approved |
0.7351 |
Intermediate Similarity |
NPD2582 |
Approved |
0.735 |
Intermediate Similarity |
NPD5575 |
Clinical (unspecified phase) |
0.7348 |
Intermediate Similarity |
NPD4584 |
Approved |
0.7346 |
Intermediate Similarity |
NPD5902 |
Approved |
0.7346 |
Intermediate Similarity |
NPD5903 |
Approved |
0.7345 |
Intermediate Similarity |
NPD8100 |
Phase 3 |
0.7339 |
Intermediate Similarity |
NPD7555 |
Discontinued |
0.7333 |
Intermediate Similarity |
NPD7620 |
Phase 2 |
0.7313 |
Intermediate Similarity |
NPD6590 |
Discontinued |
0.7313 |
Intermediate Similarity |
NPD6491 |
Clinical (unspecified phase) |
0.731 |
Intermediate Similarity |
NPD4921 |
Phase 3 |
0.731 |
Intermediate Similarity |
NPD4919 |
Phase 3 |
0.731 |
Intermediate Similarity |
NPD4920 |
Clinical (unspecified phase) |
0.7308 |
Intermediate Similarity |
NPD2189 |
Approved |
0.7308 |
Intermediate Similarity |
NPD7672 |
Approved |
0.7308 |
Intermediate Similarity |
NPD7671 |
Approved |
0.7308 |
Intermediate Similarity |
NPD2187 |
Approved |
0.7306 |
Intermediate Similarity |
NPD4925 |
Approved |
0.7303 |
Intermediate Similarity |
NPD4664 |
Clinical (unspecified phase) |
0.7286 |
Intermediate Similarity |
NPD8063 |
Discontinued |
0.7284 |
Intermediate Similarity |
NPD7169 |
Suspended |
0.7282 |
Intermediate Similarity |
NPD6991 |
Approved |
0.7277 |
Intermediate Similarity |
NPD2482 |
Clinical (unspecified phase) |
0.7277 |
Intermediate Similarity |
NPD7025 |
Clinical (unspecified phase) |
0.7277 |
Intermediate Similarity |
NPD4083 |
Discontinued |
0.7277 |
Intermediate Similarity |
NPD6550 |
Discontinued |
0.7277 |
Intermediate Similarity |
NPD7885 |
Phase 2 |
0.7277 |
Intermediate Similarity |
NPD7886 |
Phase 2 |
0.7268 |
Intermediate Similarity |
NPD1620 |
Clinical (unspecified phase) |
0.7264 |
Intermediate Similarity |
NPD6361 |
Phase 2 |
0.726 |
Intermediate Similarity |
NPD7710 |
Clinical (unspecified phase) |
0.726 |
Intermediate Similarity |
NPD5429 |
Discontinued |
0.726 |
Intermediate Similarity |
NPD5559 |
Phase 2 |
0.7255 |
Intermediate Similarity |
NPD4548 |
Discontinued |
0.7255 |
Intermediate Similarity |
NPD5999 |
Phase 2 |
0.7249 |
Intermediate Similarity |
NPD8101 |
Phase 3 |
0.7243 |
Intermediate Similarity |
NPD4429 |
Discontinued |
0.7241 |
Intermediate Similarity |
NPD6769 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD7948 |
Phase 1 |
0.7238 |
Intermediate Similarity |
NPD6262 |
Clinical (unspecified phase) |
0.7236 |
Intermediate Similarity |
NPD4021 |
Phase 2 |
0.7233 |
Intermediate Similarity |
NPD5669 |
Clinical (unspecified phase) |
0.723 |
Intermediate Similarity |
NPD7112 |
Discontinued |
0.7228 |
Intermediate Similarity |
NPD3324 |
Clinical (unspecified phase) |
0.7228 |
Intermediate Similarity |
NPD3810 |
Clinical (unspecified phase) |
0.7227 |
Intermediate Similarity |
NPD1900 |
Clinical (unspecified phase) |
0.7227 |
Intermediate Similarity |
NPD7567 |
Approved |
0.7227 |
Intermediate Similarity |
NPD5801 |
Clinical (unspecified phase) |
0.7225 |
Intermediate Similarity |
NPD4724 |
Clinical (unspecified phase) |
0.7219 |
Intermediate Similarity |
NPD5255 |
Approved |
0.7208 |
Intermediate Similarity |
NPD5917 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD5007 |
Approved |
0.7204 |
Intermediate Similarity |
NPD5067 |
Phase 2 |
0.7204 |
Intermediate Similarity |
NPD5066 |
Phase 2 |
0.72 |
Intermediate Similarity |
NPD8016 |
Phase 3 |
0.72 |
Intermediate Similarity |
NPD8017 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD5905 |
Phase 1 |
0.7184 |
Intermediate Similarity |
NPD6592 |
Clinical (unspecified phase) |
0.7177 |
Intermediate Similarity |
NPD1392 |
Approved |
0.7168 |
Intermediate Similarity |
NPD6790 |
Phase 1 |
0.7165 |
Intermediate Similarity |
NPD5100 |
Phase 3 |
0.7163 |
Intermediate Similarity |
NPD3946 |
Clinical (unspecified phase) |
0.7158 |
Intermediate Similarity |
NPD926 |
Approved |
0.7158 |
Intermediate Similarity |
NPD925 |
Approved |
0.7157 |
Intermediate Similarity |
NPD2952 |
Discontinued |
0.7157 |
Intermediate Similarity |
NPD4899 |
Clinical (unspecified phase) |
0.7157 |
Intermediate Similarity |
NPD7034 |
Discontinued |
0.715 |
Intermediate Similarity |
NPD6975 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD1602 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD5008 |
Approved |
0.7137 |
Intermediate Similarity |
NPD5051 |
Phase 1 |
0.7136 |
Intermediate Similarity |
NPD5944 |
Phase 1 |
0.7136 |
Intermediate Similarity |
NPD5945 |
Phase 1 |
0.7136 |
Intermediate Similarity |
NPD1322 |
Clinical (unspecified phase) |
0.713 |
Intermediate Similarity |
NPD3402 |
Phase 1 |
0.713 |
Intermediate Similarity |
NPD8350 |
Clinical (unspecified phase) |
0.7129 |
Intermediate Similarity |
NPD3003 |
Approved |
0.7122 |
Intermediate Similarity |
NPD7889 |
Clinical (unspecified phase) |
0.712
|
Intermediate Similarity |
NPD7201 |
Clinical (unspecified phase) |